Skip to Main Content

Paper Details

Real-world performance of SARS-Cov-2 serology tests in the United States, 2020.
PLoS One
0
2023
COVID-19, CoV, PPA, SARS, SARS-, SARS-CoV-2, auto-, diabetes, immune conditions, immunocompromised, immunocompromised or autoimmune conditions, kidney disease, obesity, patients, people
Author NameAffiliation
Natalie E Sheils
Shaun J GrannisRegenstrief Institute
Shaun J GrannisIndiana University School of Medicine
Rohit VashishtBakar Computational Health Sciences Institute, University of California san francisco
Rohit VashishtBakar Computational Health Sciences Institute, University of California san francisco
Peter J EmbiVanderbilt University Medical Center
Garrett JenkinsonMayo Clinic
Omai B Garneruniversity of california los angeles Medical Center
Lisa DahmCenter for Data-Driven Insights and Innovation, University of California Health
Carrie L ByingtonCenter for Data-Driven Insights and Innovation, University of California Health
Atul J ButteBakar Computational Health Sciences Institute, University of California san francisco
Atul J ButteCenter for Data-Driven Insights and Innovation, University of California Health
  • 1 - 12

Datasets

Release 1.2